Food and Drug Administration
Oncologic Drugs Advisory Committee
December 14, 1999
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Therapeutic Equivalence & Active control Clinical Trials, Dr. Richard Simon, DSc, FDA htm ppt
Celebrex Capsules (Celecoxib) Familial Adenomatous Polyposis (FAP), Dr. Richard Spivey, PharmD, PhD, Worldwide Regulatory Affairs Searle pdf
Indication, Reduction and Regression of Adenomatous Colorectal Polyps in Familial Adenomatous Polyposis Patients, Dr. Judy Chiao, MD, FDA htm ppt